{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Complications&page=14",
    "query": {
      "condition": "Metabolic Complications",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1666,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Complications&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metabolic+Complications&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:46:20.407Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05254002",
      "title": "A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Finerenone (BAY94-8862 ) 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin Placebo",
          "type": "DRUG"
        },
        {
          "name": "Finerenone (BAY94-8862 ) 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Finerenone Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1664,
      "start_date": "2022-06-23",
      "completion_date": "2025-03-17",
      "has_results": true,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 46,
      "location_summary": "Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more",
      "locations": [
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05254002"
    },
    {
      "nct_id": "NCT00680017",
      "title": "30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemia",
        "Kidney Disease"
      ],
      "interventions": [
        {
          "name": "ABT-335 plus rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2008-06",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2012-10-03",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 102,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Madison, Alabama + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680017"
    },
    {
      "nct_id": "NCT02065791",
      "title": "Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 4401,
      "start_date": "2014-02-17",
      "completion_date": "2018-10-30",
      "has_results": true,
      "last_update_posted_date": "2019-12-05",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 152,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065791"
    },
    {
      "nct_id": "NCT07360938",
      "title": "Drug Interaction Potential of Pro-Inflammatory Conditions",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "End Stage Renal Disease",
        "Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "None (Observational)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-11-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07360938"
    },
    {
      "nct_id": "NCT03801252",
      "title": "Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Induction of Labor Affected Fetus / Newborn"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 45 Years · Female only"
      },
      "enrollment_count": 186,
      "start_date": "2018-12-12",
      "completion_date": "2021-06-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801252"
    },
    {
      "nct_id": "NCT00768040",
      "title": "Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 39,
      "start_date": "2008-09",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00768040"
    },
    {
      "nct_id": "NCT01785849",
      "title": "Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "Etelcalcetide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 508,
      "start_date": "2013-03-12",
      "completion_date": "2014-06-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-26",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01785849"
    },
    {
      "nct_id": "NCT07780188",
      "title": "Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PCOS (Polycystic Ovary Syndrome)",
        "Obese Adolescents",
        "Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities",
        "Overweight Adolescents",
        "Irregular Menstrual Cycle",
        "Irregular Menstrual Cycles",
        "Hirsutism",
        "Hyperandrogenism"
      ],
      "interventions": [
        {
          "name": "Beef+",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "11 Years to 17 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2026-09-01",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07780188"
    },
    {
      "nct_id": "NCT01652573",
      "title": "Calcitonin for Treating X-linked Hypophosphatemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypophosphatemic Rickets, X Linked Dominant"
      ],
      "interventions": [
        {
          "name": "nasal salmon calcitonin",
          "type": "DRUG"
        },
        {
          "name": "Saline Nasal Spray Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 21,
      "start_date": "2011-03",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-31",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652573"
    },
    {
      "nct_id": "NCT03421327",
      "title": "Genetic Risk: Whether, When, and How to Tell Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Huntington Disease",
        "Hereditary Breast and Ovarian Cancer",
        "Hereditary Cancer",
        "Hereditary Non-polyposis Colon Cancer",
        "Hereditary Non-Polyposis Colorectal Cancer Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2017-09-01",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-11-15T13:46:20.407Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03421327"
    }
  ]
}